BiotechTube

MEDI-551

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Blood Cancer

Conditions

Blood Cancer, Advanced B Cell Malignancies

Trial Timeline

May 25, 2011 → Sep 15, 2015

NCT ID
NCT01957579

About MEDI-551

MEDI-551 is a phase 1 stage product being developed by AstraZeneca for Blood Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01957579. Target conditions include Blood Cancer, Advanced B Cell Malignancies.

What happened to similar drugs?

7 of 17 similar drugs in Blood Cancer were approved

Approved (7) Terminated (6) Active (7)
✅micafungin + voriconazoleAstellas PharmaApproved
✅Bunazosin + Doxazosin + ValsartinEisaiApproved
✅AliskirenNovartisApproved
✅Aliskiren and HCTZNovartisApproved
✅Aspirin 100 mg + PlaceboBayerApproved
✅Hemostatic MatrixBaxterApproved
✅losartan potassium + Comparator: PlaceboOrganonApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01957579Phase 1Completed

Competing Products

20 competing products in Blood Cancer

See all competitors
ProductCompanyStageHype Score
micafungin + voriconazoleAstellas PharmaApproved
35
CefiderocolShionogiPhase 2
35
Bunazosin + Doxazosin + ValsartinEisaiApproved
43
PegfilgrastimKyowa KirinPhase 2
35
epoetin alfaJohnson & JohnsonPhase 2/3
38
epoetin alfaJohnson & JohnsonPhase 2/3
38
epoetin alfaJohnson & JohnsonPhase 2
35
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
40
AZD6140 + PlaceboAstraZenecaPhase 1
29
NKTR-118 + moxifloxacin + PlaceboAstraZenecaPhase 1
29
Ecallantide + Cyklokapron(R)MerckPhase 2
35
DaptomycinMerckPhase 2
35
ecallantide + placeboMerckPhase 2
35
MK0859MerckPhase 1
29
Ecallantide + PlaceboMerckPhase 2
27
HSC835NovartisPhase 2
35
AliskirenNovartisApproved
35
Aliskiren and HCTZNovartisApproved
43
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo AmlodipineNovartisPhase 2
35
Darbepoetin alfaAmgenPhase 1/2
32